GYRE
NASDAQ · Biotechnology
Gyre Therapeutics Inc
$7.47
+0.40 (+5.66%)
Open$7.21
Previous Close$7.07
Day High$7.47
Day Low$7.20
52W High$11.78
52W Low$6.57
Volume—
Avg Volume72.2K
Market Cap716.79M
P/E Ratio142.59
EPS$0.05
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+300.5% upside
Current
$7.47
$7.47
Target
$29.92
$29.92
$20.05
$29.92 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 110.34M | 231.94M | 230.03M |
| Net Income | 4.76M | -34,891,358 | -29,454,556 |
| Profit Margin | 4.3% | -15.0% | -12.8% |
| EBITDA | 14.36M | -32,635,653 | -32,852,234 |
| Free Cash Flow | — | -26,269,864 | -27,800,469 |
| Rev Growth | +428.5% | -3.5% | +14.1% |
| Debt/Equity | — | 0.25 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |